Brief: Centessa Pharmaceuticals To Discontinue Clinical Development Of Lixivaptan For ADPKD

Centessa Pharmaceuticals

02/06/2022 11:46

June 2 (Reuters) - Centessa Pharmaceuticals PLC  260y.F :
    * CENTESSA PHARMACEUTICALS MAKES STRATEGIC DECISION TO
DISCONTINUE
CLINICAL DEVELOPMENT OF LIXIVAPTAN FOR AUTOSOMAL DOMINANT
POLYCYSTIC KIDNEY DISEASE (ADPKD)
    * CENTESSA PHARMACEUTICALS PLC- DISCONTINUATION OF
LIXIVAPTAN
DEVELOPMENT EXPECTED TO SIGNIFICANTLY REDUCE CASH BURN AND
EXTEND CASH RUNWAY INTO 2026
    * CENTESSA - DECISION BASED ON REASSESSMENT OF COMMERCIAL
POTENTIAL OF LIXIVAPTAN FOLLOWING RECENT OBSERVATION OF ALT/AST
ELEVATIONS IN ALERT STUDY
    * CENTESSA - CONTINUES TO FOCUS ON DEVELOPMENT OF ITS HIGH
IMPACT
RARE DISEASE AND IMMUNO-ONCOLOGY PIPELINE OF INVESTIGATIONAL
MEDICINES FOR PATIENTS

Source text for Eikon:  ID:nGNX8MYfdw 
Further company coverage:  260y.F 

 ((Reuters.Briefs@thomsonreuters.com;))